Fabry Disease: Further Considerations in Selecting a Treatment Option

Host: Charles Turck, PharmD, BCPS, BCCCP <br> Guest: Joseph William Ray, MD <br> <p>Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.</p> <p>For more information, please visit <a href="https://www.fabrazyme.com/hcp/"><span style="text-decoration-line: underline;">www.fabrazyme.com/hcp</span></a>.</p> <p style="text-align: right;">MAT-US-2107750-v1.0-08/2021</p> <p> </p>